Sort
25,944 grants matching “neurodegeneration”
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
$2,265,244Susan Abushakra · Alzheon, Inc. · R01 · FY2024 · AG
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission
$2,264,085Jessica Kirkland Caldwell · Cleveland Clinic Foundation · P20 · FY2024 · GM
Automated cell-type-specific electrophysiology for understanding circuit dysregulation in Alzheimer's Disease
$2,263,275Matthew J.m. Rowan · Emory University · RF1 · FY2022 · AG
COBRE GRANT
$2,262,935Marwan Noel Sabbagh · Cleveland Clinic Foundation · P20 · FY2019 · GM
Leveraging Big Data to Improve Women's Health (BD-WH)
$2,261,838Heather R Desaire · University Of Kansas Lawrence · P20 · FY2024 · GM
Investigating the mechanisms by which systemic inflammation promotes Alzheimerâs disease: Asthma as a model and modifiable risk factor
$2,261,120Melissa A Rosenkranz · University Of Wisconsin-Madison · RF1 · FY2023 · AG
Bidirectional interactions between sleep and Alzheimer's disease: Functional dissection of the brain transcriptome in humans and Drosophila
$2,261,078Paul J Shaw · Washington University · RF1 · FY2021 · AG
Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2.
$2,258,215Vojo P Deretic · University Of New Mexico Health Scis Ctr · P20 · FY2024 · GM
Potassium Channels and Dendritic Function in Hippocampal Pyramidal Neurons
$2,257,955Dax A Hoffman · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2022 · HD
Gatekeepers of Mitochondrial NAD+
$2,252,940Xiaolu Ang Cambronne · University Of Texas At Austin · DP2 · FY2017 · GM
Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission
$2,252,411Jessica Kirkland Caldwell · Cleveland Clinic Foundation · P20 · FY2022 · GM
Molecular Mechanisms linking Aging, Abeta Proteotoxicity and Neurodegeneration
$2,251,056Jeffery W Kelly · Scripps Research Institute, The · P01 · FY2009 · AG
Development of a MT-stabilizing agent for the treatment of tauopathies
$2,250,355Conor Caffrey · University Of California, San Diego · U01 · FY2025 · AG
Autophagy, Inflammation and Metabolism (AIM) in Disease Center - Phase 2.
$2,249,540Vojo P Deretic · University Of New Mexico Health Scis Ctr · P20 · FY2025 · GM
Epidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic, Washington Heights, Inwood, Columbia Aging Project (WHICAP)
$2,246,093Richard Mayeux · Columbia University Health Sciences · R01 · FY2025 · AG
Identification of small molecule inhibitors of tau pathology utilizing a novel primary neuronal assay.
$2,245,547Kurt R. Brunden · University Of Pennsylvania · RF1 · FY2020 · AG
Imaging and Reversibility of Cellular and Network Metabolic Dysfunction in Alzheimer's Disease
$2,244,795Manu S Goyal · Washington University · RF1 · FY2022 · AG
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).
$2,244,681Niccolo Terrando · Duke University · RF1 · FY2022 · AG
Genetic Architecture of Alzheimerâs disease Proteinopathies
$2,243,331M. Ilyas Kamboh · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AG
Phosphoinositide-calcium Signaling In Cell Regulation
$2,241,746Tamas Balla · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2025 · HD
National Center for Drug Discovery in Neurodegeneration
$2,238,265Ross L Stein · Brigham And Women'S Hospital · U24 · FY2008 · NS
Senescent cell mapping, identification and validation for human somatic and reproductive tissues
$2,237,050Birgit Schilling · Buck Institute For Research On Aging · U54 · FY2023 · AG
Neurological and digital correlates of cognition in Older Mandarin-speaking Adults
$2,236,070William Tzu-Lung Hu · Rutgers Biomedical And Health Sciences · RF1 · FY2023 · AG
Utilizing TALEN technology to regulate human microRNA's
$2,235,000Ryan M O'Connell · University Of Utah · DP2 · FY2013 · GM
Frontotemporal Dementias: Genotypes and Phenotypes
$2,234,654Virginia M Lee · University Of Pennsylvania · P01 · FY2019 · AG